223 related articles for article (PubMed ID: 26080810)
1. Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition.
Gupta P; Garg T; Tanmay M; Arora S
Crit Rev Ther Drug Carrier Syst; 2015; 32(3):247-75. PubMed ID: 26080810
[TBL] [Abstract][Full Text] [Related]
2. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
Kou L; Sun R; Bhutia YD; Yao Q; Chen R
Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity.
Wei Z; Yuan S; Hao J; Fang X
Eur J Pharm Biopharm; 2013 Feb; 83(2):266-74. PubMed ID: 23089310
[TBL] [Abstract][Full Text] [Related]
5. Non-ionic Surfactants as a P-Glycoprotein(P-gp) Efflux Inhibitor for Optimal Drug Delivery-A Concise Outlook.
Rathod S; Desai H; Patil R; Sarolia J
AAPS PharmSciTech; 2022 Jan; 23(1):55. PubMed ID: 35043278
[TBL] [Abstract][Full Text] [Related]
6. Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.
Sajid A; Lusvarghi S; Murakami M; Chufan EE; Abel B; Gottesman MM; Durell SR; Ambudkar SV
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29609-29617. PubMed ID: 33168729
[TBL] [Abstract][Full Text] [Related]
7. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
Bansal T; Jaggi M; Khar RK; Talegaonkar S
J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
[TBL] [Abstract][Full Text] [Related]
8. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
9. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
11. Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review.
Patel D; Sethi N; Patel P; Shah S; Patel K
Eur J Pharm Biopharm; 2024 May; 198():114267. PubMed ID: 38514020
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Potential P-gp Substrates: Main Aspects to Choose the Adequate Permeability Model for Assessing Gastrointestinal Drug Absorption.
da Silva Junior JB; Dezani TM; Dezani AB; dos Reis Serra CH
Mini Rev Med Chem; 2015; 15(10):858-71. PubMed ID: 25963568
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
Varma MV; Ashokraj Y; Dey CS; Panchagnula R
Pharmacol Res; 2003 Oct; 48(4):347-59. PubMed ID: 12902205
[TBL] [Abstract][Full Text] [Related]
15. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier.
Kabanov AV; Batrakova EV; Miller DW
Adv Drug Deliv Rev; 2003 Jan; 55(1):151-64. PubMed ID: 12535579
[TBL] [Abstract][Full Text] [Related]
16. Xanthones as P-glycoprotein modulators and their impact on drug bioavailability.
Silva V; Gil-Martins E; Silva B; Rocha-Pereira C; Sousa ME; Remião F; Silva R
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):441-482. PubMed ID: 33283552
[No Abstract] [Full Text] [Related]
17. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
Fromm MF
Int J Clin Pharmacol Ther; 2000 Feb; 38(2):69-74. PubMed ID: 10706193
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols.
Jodoin J; Demeule M; Beliveau R
Biochim Biophys Acta; 2002 Jan; 1542(1-3):149-59. PubMed ID: 11853888
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
Callaghan R; Luk F; Bebawy M
Drug Metab Dispos; 2014 Apr; 42(4):623-31. PubMed ID: 24492893
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines.
Nielsen D; Skovsgaard T
Biochim Biophys Acta; 1992 Jul; 1139(3):169-83. PubMed ID: 1352705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
